Neel Mistry - Profile and Journalist Details

Find journalists that align with your industry, location and vision. Unlock Neel Mistry's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.

Get connected with journalists today
Neel Mistry

Neel Mistry

Verified

Contributor, 2 Minute Medicine

Boston

Final Covers

Health and wellness

Doesn’t Cover

Baseball, College Basketball

Journalist Type

Seniority Positions

Industries

Medium Formats

Content

Total articles 350

  • Nivolumab plus ipilimumab improves progression-free survival in metastatic colorectal cancer

    By Neel Mistry| 2 Minute Medicine Verified 1. Progression-free survival was significantly greater in the nivolumab plus ipilimumab group compared to nivolumab alone. 2. Treatment-related adverse events were slightly higher in nivolumab plus ipilimumab. Evidence Rating Level: 1 (Excellent) Study Rundown: Microsatellite instability-high metastatic colorectal cancer is an aggressive disease with limited treatment options.

    By Neel Mistry · 2 Minute Medicine

    Apr. 03, 2025

  • Less frequent mammography is non-inferior to annual screening for breast cancer survival in women after curative treatment

    By Neel Mistry| 2 Minute Medicine Verified 1. 5-year breast cancer-specific survival was comparable between annual and less frequent mammography groups. 2. Less-frequent mammographic surveillance showed a similar recurrence-free interval. Evidence Rating Level: 1 (Excellent)Study Rundown: Breast cancer surveillance guidelines vary worldwide, with uncertainty regarding the necessity of annual mammograms for survivors.

    By Neel Mistry · 2 Minute Medicine

    Apr. 02, 2025

  • Nivolumab plus ipilimumab improves progression-free survival in metastatic colorectal cancer

    By Neel Mistry| 2 Minute Medicine Verified 1. Progression-free survival was significantly greater in the nivolumab plus ipilimumab group compared to nivolumab alone. 2. Treatment-related adverse events were slightly higher in nivolumab plus ipilimumab. Evidence Rating Level: 1 (Excellent) Study Rundown: Microsatellite instability-high metastatic colorectal cancer is an aggressive disease with limited treatment options.

    By Neel Mistry · 2 Minute Medicine

    Apr. 03, 2025

As seen in

Company Info

2 Minute Medicine

The 2 Minute Medicine®, Inc. publishing organization provides objective and concise reports of high-impact medical news to the general public and health professionals. 2 Minute Medicine is a leading licensor of original medical reports to news organizations, hospitals, and brands. www.2minutemedicine.com

'+1 857-600-0194

Founded: 2012